Edy Firmina Pereira

Edy Firmina Pereira

Auto-generated profile, based on publicly available information

Edy Firmina Pereira

Universidade Federal de Mato Grosso do Sul, Campo Grande, MS, Brazil

Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2019 in Jornal Brasileiro de Pneumologia
Verified
Journal Article
Open access
PDF file
UAUrsulla Vilella Andrade
Ursulla Vilella Andrade
SOSandra M.V.L. DE OLIVEIRA
Sandra M.V.L. DE OLIVEIRA
MCMarilene Rodrigues Chang
Marilene Rodrigues Chang
EPEdy Firmina Pereira
Edy Firmina Pereira
AMAna Paula da Costa Marques
Ana Paula da Costa Marques
APAnamaria Mello Miranda Paniago
Anamaria Mello Miranda Paniago
Objective: To evaluate the treatment compliance of patients with paracoccidioidomycosis. Methods: We studied 188 patients with paracoccidioidomycosis admitted to a tertiary referral hospital in the Central-West Region of Brazil from 2000 to 2010, to assess their compliance to treatment. In order to be considered compliant, patients needed to present two established criteria: (1) receive medicines from the pharmacy, and (2) achieve a self-reported utilization of at least 80% of the dispensed antifungal compounds prescribed since their previous appointment. Results: Most patients were male (95.7%), had the chronic form of the disease (94.2%), and were treated with cotrimoxazole (86.2%). Only 44.6% of patients were treatment compliant. The highest loss to follow-up was observed in the first 4 months of treatment (p < 0.02). Treatment compliance was higher for patients with than for those without pulmonary involvement (OR: 2.986; 95%CI 1.351-6.599), and higher for patients with than without tuberculosis as co-morbidity (OR: 2.763; 95%CI 1.004-7.604). Conclusions: Compliance to paracoccidioidomycosis treatment was low, and the period with the highest loss to follow-up corresponds to the first four months. Pulmonary paracoccidioidal involvement or tuberculosis comorbidity predicts a higher compliance to paracoccidioidomycosis therapy.